Combination of chir99021 and valproic acid for treating hearing loss

CHIR99021 or a pharmaceutically acceptable salt thereof and valproic acid (VPA) or a pharmaceutically acceptable salt thereof for use in treating sensorineural hearing loss in a human patient, wherein the average of the patient's hearing thresholds across 0.5 kHz, 1 kHz, 2 kHz and 4 kHz is greater than 40 dB HL and no more than 70 dB HL when measured by pure tone audiometry prior to the treatment.

CHIR99021 or a pharmaceutically acceptable salt thereof and valproic acid (VPA) or a pharmaceutically acceptable salt thereof for use in treating sensorineural hearing loss in a human patient, wherein the patient has a standard word recognition score of 60% or less prior to the treatment.

CHIR99021 or a pharmaceutically acceptable salt thereof and valproic acid (VPA) or a pharmaceutically acceptable salt thereof for use in treating sensorineural hearing loss in a human patient, wherein the patient has a words-in-noise score of 50% or less prior to the treatment.

CHIR99021 or a pharmaceutically acceptable salt thereof and valproic acid (VPA) or a pharmaceutically acceptable salt thereof for use in treating tinnitus in a human patient with sensorineural hearing loss, wherein the tinnitus is diagnosed using one or more of the methods selected from the group consisting of:

• tinnitus functional index (TFI), tinnitus handicap index (THI), tinnitus reaction questionnaire (TRQ), tinnitus severity index (TSI), and tinnitus handicap questionnaire (THQ).

A hair cell regeneration agent(s) for use in treating sensorineural hearing loss in a human patient, wherein the sensorineural hearing loss is moderate or moderately severe sensorineural hearing loss

A hair cell regeneration agent(s) for use in treating sensorineural hearing loss in a human patient, wherein the average of the patient's hearing thresholds across 0.5 kHz, 1 kHz, 2 kHz and 4 kHz is greater than 40 dB HL and no more than 70 dB HL when measured by pure tone audiometry prior to the treatment.

A hair cell regeneration agent(s) for use in treating sensorineural hearing loss in a human patient, wherein the patient has a standard word recognition score of 60% or less prior to the treatment.

A hair cell regeneration agent(s) for use in treating sensorineural hearing loss in a human patient, wherein the patient has a words-in-noise score of 50% or less prior to the treatment.

A hair cell regeneration agent(s) for use in treating tinnitus in a human patient with sensorineural hearing loss, wherein the tinnitus is diagnosed using one or more of the methods selected from the group consisting of;

• tinnitus functional index (TFI), tinnitus handicap index (THI), tinnitus reaction questionnaire (TRQ), tinnitus severity index (TSI), and tinnitus handicap questionnaire (THQ).

The hair cell regeneration agent(s) for use according to claim 47, wherein the sensorineural hearing loss is mild, moderate or moderately severe sensorineural hearing loss.